IM Cannabis Corp
NASDAQ:IMCC
Decide at what price you'd be comfortable buying and we'll help you stay ready.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
|
Walt Disney Co
NYSE:DIS
|
US |
|
PayPal Holdings Inc
NASDAQ:PYPL
|
US |
P/B
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Price to Book (P/B) ratio compares a company`s market value to its book value. It shows how much investors are paying for each dollar of net assets on the balance sheet.
Valuation Scenarios
If P/B returns to its 3-Year Average (0.8), the stock would be worth $0.12 (57% downside from current price).
| Scenario | P/B Value | Implied Price | Upside/Downside |
|---|---|---|---|
| Current Multiple | 1.8 | $0.28 |
0%
|
| 3-Year Average | 0.8 | $0.12 |
-57%
|
| 5-Year Average | 0.4 | $0.06 |
-78%
|
| Industry Average | 1.3 | $0.21 |
-26%
|
| Country Average | 2.7 | $0.42 |
+46%
|
Forward P/B
Today’s price vs future total equity
Peer Comparison
| Market Cap | P/B | P/E | ||||
|---|---|---|---|---|---|---|
| CA |
I
|
IM Cannabis Corp
NASDAQ:IMCC
|
3.1m USD | 1.8 | -2.1 | |
| US |
|
Eli Lilly and Co
NYSE:LLY
|
835.2B USD | 31.5 | 40.5 | |
| US |
|
Johnson & Johnson
NYSE:JNJ
|
547.8B USD | 6.7 | 26 | |
| CH |
|
Roche Holding AG
SIX:ROG
|
248.4B CHF | 7.7 | 20.1 | |
| UK |
|
AstraZeneca PLC
LSE:AZN
|
216.4B GBP | 5.9 | 28 | |
| CH |
|
Novartis AG
SIX:NOVN
|
223.1B CHF | 5.9 | 19.5 | |
| US |
|
Merck & Co Inc
NYSE:MRK
|
276.9B USD | 5.3 | 15.2 | |
| IE |
E
|
Endo International PLC
LSE:0Y5F
|
244.4B USD | -58.7 | -83.6 | |
| DK |
|
Novo Nordisk A/S
CSE:NOVO B
|
1.1T DKK | 6 | 11.4 | |
| US |
|
Pfizer Inc
NYSE:PFE
|
153.5B USD | 1.8 | 19.8 | |
| US |
|
Bristol-Myers Squibb Co
NYSE:BMY
|
118.2B USD | 6.4 | 16.8 |
Market Distribution
| Min | 0 |
| 30th Percentile | 1.6 |
| Median | 2.7 |
| 70th Percentile | 4.9 |
| Max | 1 402.4 |
Other Multiples
IM Cannabis Corp
Glance View
IM Cannabis Corp. engages in the production and sale of medical cannabis products. The company is headquartered in Vancouver, British Columbia and currently employs 283 full-time employees. The firm operates in Israel through its commercial relationship with Focus Medical Herbs Ltd. (Focus Medical), where it cultivates, imports and distributes cannabis to medical patients, data and patient insights. The firm also operates medical cannabis retail pharmacies, online platforms, distribution centers and logistical hubs in Israel. The firm operates in Germany through Adjupharm GmbH (Adjupharm), where it is a certified medical cannabis producer and distributor with wholesale, narcotics handling, manufacturing, procurement, storage, and distribution licenses. The firm operates in Canada through Trichome JWC Acquisition Corp. d/b/a JWC and MYM Nutraceuticals Inc., where it cultivates and processes cannabis for the adult-use market at its Ontario and Nova Scotia facilities under the WAGNERS and Highland Grow brands.
